SECTOR / PHARMA
Know which evidence earns a new prescription.
Move commercial learning upstream. Test the clinical story while the asset is still in Phase II.
0 in 3
New drugs often miss prelaunch expectations. The molecule is only part of the bet. Know which evidence earns physician confidence before the launch plan hardens.
THE DECISION
Which evidence makes a physician prescribe a new drug?
Rank the clinical story, access path, and support program before launch strategy hardens. Bring commercial learning into Phase II instead of waiting for Phase III.
VALIDATED WEEKLY
0.73
Mean rank agreement
43 design-filtered human studies
Confidence, with every report.
Every report carries graded confidence. Each week, we test the system against held-out human data and publish the full benchmark, including mid-range results and failures.
Read the validation paper ↗